Company intelligence / Profile preview

Shanghai Yunying Bio-pharm Technology

Shanghai, Shanghai, Chinapitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

Shanghai Yunying Medical Technology is developing several recombinant oncolytic viruses targeting advanced cancers. Their lead program—a recombinant herpes simplex type I vector targeting multiple immune checkpoints—is currently in early phase clinical trials for advanced malignant solid tumors. Other candidates remain at the pre-clinical stage. The company leverages cutting-edge genomics technologies to provide comprehensive precision medicine services throughout China.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyRecombinant protein therapy
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Yunying Bio-pharm Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Yunying Bio-pharm Technology.

Explore the full profile